Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer

Pharmacology and Therapeutics

Volumn 164, Issue , 2016, Pages 152-169

  Wigerup, Caroline ^a   Påhlman, Sven ^a   Bexell, Daniel ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Cancer; Hypoxia; Hypoxia inducible factor (HIF); Neuroblastoma; Paraganglioma; Pheochromocytoma

Indexed keywords

2 METHOXYESTRADIOL; AMPHOTERICIN B; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; DNA TOPOISOMERASE INHIBITOR; HEAT SHOCK PROTEIN; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; POLYAMIDE; PRODRUG; PROTEASOME INHIBITOR; PROTEIN INHIBITOR; THIOREDOXIN; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; HYPOXIA INDUCIBLE FACTOR 1;

CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STEM CELL; CANCER THERAPY; CELL INVASION; GENOMIC INSTABILITY; HUMAN; IMMUNE RESPONSE; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NEURAL CREST; NONHUMAN; NUCLEAR REPROGRAMMING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR HYPOXIA; TUMOR IMMUNITY; TUMOR VASCULARIZATION; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BIOSYNTHESIS; CELL DIFFERENTIATION; CELL HYPOXIA; CELL PROLIFERATION; DRUG RESISTANCE; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; PHYSIOLOGY; TRANSCRIPTION INITIATION;

APOPTOSIS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL DIFFERENTIATION; CELL HYPOXIA; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PRODRUGS; RNA, MESSENGER; TRANSCRIPTIONAL ACTIVATION;

EID: 84971645609     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2016.04.009     Document Type: Review

References (289)

1. Aebersold, D.M., Burri, P., Beer, K.T., Laissue, J., Djonov, V., Greiner, R.H., Semenza, G.L., Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 61 (2001), 2911–2916.
2. Amar, L., Baudin, E., Burnichon, N., Peyrard, S., Silvera, S., Bertherat, J. Plouin, P.F., Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab 92 (2007), 3822–3828.
3. Amelio, I., Melino, G., The p53 family and the hypoxia-inducible factors (HIFs): determinants of cancer progression. Trends Biochem Sci 40 (2015), 425–434.
4. An, W.G., Kanekal, M., Simon, M.C., Maltepe, E., Blagosklonny, M.V., Neckers, L.M., Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature 392 (1998), 405–408.
5. Antonioli, L., Blandizzi, C., Pacher, P., Hasko, G., Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer 13 (2013), 842–857.
6. Ban, H.S., Uto, Y., Nakamura, H., Hypoxia-inducible factor inhibitors: a survey of recent patented compounds (2004 - 2010). Expert Opin Ther Pat 21 (2011), 131–146.
7. Barsoum, I.B., Smallwood, C.A., Siemens, D.R., Graham, C.H., A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res 74 (2014), 665–674.
8. Bayley, J.P., van Minderhout, I., Hogendoorn, P.C., Cornelisse, C.J., van der Wal, A., Prins, F.A. Taschner, P.E., Sdhd and SDHD/H19 knockout mice do not develop paraganglioma or pheochromocytoma. PLoS One, 4, 2009, e7987.
9. Beasley, N.J., Leek, R., Alam, M., Turley, H., Cox, G.J., Gatter, K. Harris, A.L., Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res 62 (2002), 2493–2497.
10. Bellot, G., Garcia-Medina, R., Gounon, P., Chiche, J., Roux, D., Pouyssegur, J., Mazure, N.M., Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains. Mol Cell Biol 29 (2009), 2570–2581.
11. Beppu, K., Nakamura, K., Linehan, W.M., Rapisarda, A., Thiele, C.J., Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells. Cancer Res 65 (2005), 4775–4781.
12. Berry, T., Luther, W., Bhatnagar, N., Jamin, Y., Poon, E., Sanda, T. George, R.E., The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer Cell 22 (2012), 117–130.
13. Bersten, D.C., Sullivan, A.E., Peet, D.J., Whitelaw, M.L., bHLH-PAS proteins in cancer. Nat Rev Cancer 13 (2013), 827–841.
14. Bertout, J.A., Majmundar, A.J., Gordan, J.D., Lam, J.C., Ditsworth, D., Keith, B. Simon, M.C., HIF2alpha inhibition promotes p53 pathway activity, tumor cell death, and radiation responses. Proc Natl Acad Sci U S A 106 (2009), 14391–14396.
15. Bertout, J.A., Patel, S.A., Simon, M.C., The impact of O2 availability on human cancer. Nat Rev Cancer 8 (2008), 967–975.
16. Bertozzi, D., Marinello, J., Manzo, S.G., Fornari, F., Gramantieri, L., Capranico, G., The natural inhibitor of DNA topoisomerase I, camptothecin, modulates HIF-1alpha activity by changing miR expression patterns in human cancer cells. Mol Cancer Ther 13 (2014), 239–248.
17. Birner, P., Gatterbauer, B., Oberhuber, G., Schindl, M., Rossler, K., Prodinger, A. Hainfellner, J.A., Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: its impact on prognosis and on neoangiogenesis. Cancer 92 (2001), 165–171.
18. Birner, P., Schindl, M., Obermair, A., Breitenecker, G., Oberhuber, G., Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 7 (2001), 1661–1668.
19. Birner, P., Schindl, M., Obermair, A., Plank, C., Breitenecker, G., Oberhuber, G., Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 60 (2000), 4693–4696.
20. Bohonowych, J.E., Peng, S., Gopal, U., Hance, M.W., Wing, S.B., Argraves, K.M. Isaacs, J.S., Comparative analysis of novel and conventional Hsp90 inhibitors on HIF activity and angiogenic potential in clear cell renal cell carcinoma: implications for clinical evaluation. BMC Cancer, 11, 2011, 520.
21. Borad, M.J., Reddy, S.G., Bahary, N., Uronis, H.E., Sigal, D., Cohn, A.L. Ryan, D.P., Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer. J Clin Oncol 33 (2015), 1475–1481.
22. Bos, R., van der Groep, P., Greijer, A.E., Shvarts, A., Meijer, S., Pinedo, H.M. van der Wall, E., Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 97 (2003), 1573–1581.
23. Bos, R., Zhong, H., Hanrahan, C.F., Mommers, E.C., Semenza, G.L., Pinedo, H.M. van der Wall, E., Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst 93 (2001), 309–314.
24. Bracken, C.P., Fedele, A.O., Linke, S., Balrak, W., Lisy, K., Whitelaw, M.L., Peet, D.J., Cell-specific regulation of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha stabilization and transactivation in a graded oxygen environment. J Biol Chem 281 (2006), 22575–22585.
25. Braekeveldt, N., Wigerup, C., Gisselsson, D., Mohlin, S., Merselius, M., Beckman, S. Bexell, D., Neuroblastoma patient-derived orthotopic xenografts retain metastatic patterns and geno- and phenotypes of patient tumours. Int J Cancer 136 (2015), E252–E261.
26. Braekeveldt, N., Wigerup, C., Tadeo, I., Beckman, S., Sanden, C., Jonsson, J. Bexell, D., Neuroblastoma patient-derived orthotopic xenografts reflect the microenvironmental hallmarks of aggressive patient tumours. Cancer Lett 375:2 (2016), 384–389.
27. Branco-Price, C., Zhang, N., Schnelle, M., Evans, C., Katschinski, D.M., Liao, D. Johnson, R.S., Endothelial cell HIF-1alpha and HIF-2alpha differentially regulate metastatic success. Cancer Cell 21 (2012), 52–65.
28. Bratslavsky, G., Sudarshan, S., Neckers, L., Linehan, W.M., Pseudohypoxic pathways in renal cell carcinoma. Clin Cancer Res 13 (2007), 4667–4671.
29. Bristow, R.G., Hill, R.P., Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 8 (2008), 180–192.
30. Brizel, D.M., Scully, S.P., Harrelson, J.M., Layfield, L.J., Bean, J.M., Prosnitz, L.R., Dewhirst, M.W., Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56 (1996), 941–943.
31. Brown, J.M., Wilson, W.R., Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4 (2004), 437–447.
32. Brown, L.M., Cowen, R.L., Debray, C., Eustace, A., Erler, J.T., Sheppard, F.C. Williams, K.J., Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1. Mol Pharmacol 69 (2006), 411–418.
33. Burri, P., Djonov, V., Aebersold, D.M., Lindel, K., Studer, U., Altermatt, H.J. Gruber, G., Significant correlation of hypoxia-inducible factor-1alpha with treatment outcome in cervical cancer treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 56 (2003), 494–501.
34. Cairns, R.A., Kalliomaki, T., Hill, R.P., Acute (cyclic) hypoxia enhances spontaneous metastasis of KHT murine tumors. Cancer Res 61 (2001), 8903–8908.
35. Calvani, M., Trisciuoglio, D., Bergamaschi, C., Shoemaker, R.H., Melillo, G., Differential involvement of vascular endothelial growth factor in the survival of hypoxic colon cancer cells. Cancer Res 68 (2008), 285–291.
36. Carmeliet, P., Dor, Y., Herbert, J.M., Fukumura, D., Brusselmans, K., Dewerchin, M. Keshert, E., Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394 (1998), 485–490.
37. Carroll, V.A., Ashcroft, M., Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel–Lindau function: implications for targeting the HIF pathway. Cancer Res 66 (2006), 6264–6270.
38. Ceradini, D.J., Kulkarni, A.R., Callaghan, M.J., Tepper, O.M., Bastidas, N., Kleinman, M.E. Gurtner, G.C., Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 10 (2004), 858–864.
39. Chawla, S.P., Cranmer, L.D., Van Tine, B.A., Reed, D.R., Okuno, S.H., Butrynski, J.E. Ganjoo, K.N., Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. J Clin Oncol 32 (2014), 3299–3306.
40. Chen, D., Li, M., Luo, J., Gu, W., Direct interactions between HIF-1 alpha and Mdm2 modulate p53 function. J Biol Chem 278 (2003), 13595–13598.
41. Chun, Y.S., Yeo, E.J., Choi, E., Teng, C.M., Bae, J.M., Kim, M.S., Park, J.W., Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. Biochem Pharmacol 61 (2001), 947–954.
42. Claffey, K.P., Brown, L.F., del Aguila, L.F., Tognazzi, K., Yeo, K.T., Manseau, E.J., Dvorak, H.F., Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res 56 (1996), 172–181.
43. Clambey, E.T., McNamee, E.N., Westrich, J.A., Glover, L.E., Campbell, E.L., Jedlicka, P. Eltzschig, H.K., Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa. Proc Natl Acad Sci U S A 109 (2012), E2784–E2793.
44. Coltella, N., Valsecchi, R., Ponente, M., Ponzoni, M., Bernardi, R., Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARalpha and PLZF-RARalpha-Driven Leukemia. Clin Cancer Res 21 (2015), 3685–3694.
45. Comerford, K.M., Wallace, T.J., Karhausen, J., Louis, N.A., Montalto, M.C., Colgan, S.P., Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 62 (2002), 3387–3394.
46. Comino-Mendez, I., de Cubas, A.A., Bernal, C., Alvarez-Escola, C., Sanchez-Malo, C., Ramirez-Tortosa, C.L. Cascon, A., Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis. Hum Mol Genet 22 (2013), 2169–2176.
47. Cook, K.M., Hilton, S.T., Mecinovic, J., Motherwell, W.B., Figg, W.D., Schofield, C.J., Epidithiodiketopiperazines block the interaction between hypoxia-inducible factor-1alpha (HIF-1alpha) and p300 by a zinc ejection mechanism. J Biol Chem 284 (2009), 26831–26838.
48. Corzo, C.A., Condamine, T., Lu, L., Cotter, M.J., Youn, J.I., Cheng, P. Gabrilovich, D.I., HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med 207 (2010), 2439–2453.
49. Crosby, M.E., Kulshreshtha, R., Ivan, M., Glazer, P.M., MicroRNA regulation of DNA repair gene expression in hypoxic stress. Cancer Res 69 (2009), 1221–1229.
50. Dahia, P.L., Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. Nat Rev Cancer 14 (2014), 108–119.
51. Dales, J.P., Garcia, S., Meunier-Carpentier, S., Andrac-Meyer, L., Haddad, O., Lavaut, M.N. Charpin, C., Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients. Int J Cancer 116 (2005), 734–739.
52. Dang, C.V., Kim, J.W., Gao, P., Yustein, J., The interplay between MYC and HIF in cancer. Nat Rev Cancer 8 (2008), 51–56.
53. Daponte, A., Ioannou, M., Mylonis, I., Simos, G., Minas, M., Messinis, I.E., Koukoulis, G., Prognostic significance of Hypoxia-Inducible Factor 1 alpha(HIF-1 alpha) expression in serous ovarian cancer: an immunohistochemical study. BMC Cancer, 8, 2008, 335.
54. De Jaeger, K., Kavanagh, M.C., Hill, R.P., Relationship of hypoxia to metastatic ability in rodent tumours. Br J Cancer 84 (2001), 1280–1285.
55. DeBerardinis, R.J., Lum, J.J., Hatzivassiliou, G., Thompson, C.B., The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7 (2008), 11–20.
56. Denny, W.A., The role of hypoxia-activated prodrugs in cancer therapy. Lancet Oncol 1 (2000), 25–29.
57. Dewhirst, M.W., Cao, Y., Moeller, B., Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 8 (2008), 425–437.
58. DiSilvestro, P.A., Ali, S., Craighead, P.S., Lucci, J.A., Lee, Y.C., Cohn, D.E. Monk, B.J., Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study. J Clin Oncol 32 (2014), 458–464.
59. Doedens, A.L., Stockmann, C., Rubinstein, M.P., Liao, D., Zhang, N., DeNardo, D.G. Johnson, R.S., Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res 70 (2010), 7465–7475.
60. Dunbar, E.M., Coats, B.S., Shroads, A.L., Langaee, T., Lew, A., Forder, J.R. Stacpoole, P.W., Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors. Investig New Drugs 32 (2014), 452–464.
61. Dvorak, H.F., Nagy, J.A., Feng, D., Brown, L.F., Dvorak, A.M., Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 237 (1999), 97–132.
62. Eisenhofer, G., Huynh, T.T., Pacak, K., Brouwers, F.M., Walther, M.M., Linehan, W.M. Elkahloun, A.G., Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel–Lindau syndrome. Endocr Relat Cancer 11 (2004), 897–911.
63. Ellis, L.M., Hicklin, D.J., VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8 (2008), 579–591.
64. Erler, J.T., Bennewith, K.L., Cox, T.R., Lang, G., Bird, D., Koong, A. Giaccia, A.J., Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 15 (2009), 35–44.
65. Erler, J.T., Bennewith, K.L., Nicolau, M., Dornhofer, N., Kong, C., Le, Q.T. Giaccia, A.J., Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440 (2006), 1222–1226.
66. Erler, J.T., Cawthorne, C.J., Williams, K.J., Koritzinsky, M., Wouters, B.G., Wilson, C. Dive, C., Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol Cell Biol 24 (2004), 2875–2889.
67. Esteban, M.A., Tran, M.G., Harten, S.K., Hill, P., Castellanos, M.C., Chandra, A. Maxwell, P.H., Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. Cancer Res 66 (2006), 3567–3575.
68. Falchook, G.S., Wheler, J.J., Naing, A., Jackson, E.F., Janku, F., Hong, D. Kurzrock, R., Targeting hypoxia-inducible factor-1alpha (HIF-1alpha) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab. Oncotarget 5 (2014), 10280–10292.
69. Fan, Y., Li, H., Ma, X., Gao, Y., Chen, L., Li, X. Zhang, X., Prognostic Significance of Hypoxia-Inducible Factor Expression in Renal Cell Carcinoma: A PRISMA-compliant Systematic Review and Meta-Analysis. Medicine (Baltimore), 94, 2015, e1646.
70. Favier, J., Briere, J.J., Burnichon, N., Riviere, J., Vescovo, L., Benit, P. Gimenez-Roqueplo, A.P., The Warburg effect is genetically determined in inherited pheochromocytomas. PLoS One, 4, 2009, e7094.
71. Forsythe, J.A., Jiang, B.H., Iyer, N.V., Agani, F., Leung, S.W., Koos, R.D., Semenza, G.L., Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16 (1996), 4604–4613.
72. Franovic, A., Holterman, C.E., Payette, J., Lee, S., Human cancers converge at the HIF-2alpha oncogenic axis. Proc Natl Acad Sci U S A 106 (2009), 21306–21311.
73. Fritz, A., Walch, A., Piotrowska, K., Rosemann, M., Schaffer, E., Weber, K. Atkinson, M.J., Recessive transmission of a multiple endocrine neoplasia syndrome in the rat. Cancer Res 62 (2002), 3048–3051.
74. Gatenby, R.A., Kessler, H.B., Rosenblum, J.S., Coia, L.R., Moldofsky, P.J., Hartz, W.H., Broder, G.J., Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 14 (1988), 831–838.
75. Generali, D., Berruti, A., Brizzi, M.P., Campo, L., Bonardi, S., Wigfield, S. Fox, S.B., Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clin Cancer Res 12 (2006), 4562–4568.
76. Giatromanolaki, A., Koukourakis, M.I., Sivridis, E., Turley, H., Talks, K., Pezzella, F. Harris, A.L., Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer 85 (2001), 881–890.
77. Gilkes, D.M., Chaturvedi, P., Bajpai, S., Wong, C.C., Wei, H., Pitcairn, S. Semenza, G.L., Collagen prolyl hydroxylases are essential for breast cancer metastasis. Cancer Res 73 (2013), 3285–3296.
78. Gnarra, J.R., Tory, K., Weng, Y., Schmidt, L., Wei, M.H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F.M., Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7 (1994), 85–90.
79. Gordan, J.D., Bertout, J.A., Hu, C.J., Diehl, J.A., Simon, M.C., HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell 11 (2007), 335–347.
80. Gordan, J.D., Thompson, C.B., Simon, M.C., HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell 12 (2007), 108–113.
81. Gorlach, A., Kietzmann, T., Superoxide and derived reactive oxygen species in the regulation of hypoxia-inducible factors. Methods Enzymol 435 (2007), 421–446.
82. Graeber, T.G., Osmanian, C., Jacks, T., Housman, D.E., Koch, C.J., Lowe, S.W., Giaccia, A.J., Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379 (1996), 88–91.
83. Gray, L.H., Conger, A.D., Ebert, M., Hornsey, S., Scott, O.C., The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 26 (1953), 638–648.
84. Greenberger, L.M., Horak, I.D., Filpula, D., Sapra, P., Westergaard, M., Frydenlund, H.F. Orum, H., A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Mol Cancer Ther 7 (2008), 3598–3608.
85. Greene, L.A., Tischler, A.S., Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci U S A 73 (1976), 2424–2428.
86. Gustafsson, M.V., Zheng, X., Pereira, T., Gradin, K., Jin, S., Lundkvist, J. Bondesson, M., Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell 9 (2005), 617–628.
87. Guzy, R.D., Sharma, B., Bell, E., Chandel, N.S., Schumacker, P.T., Loss of the SdhB, but Not the SdhA, subunit of complex II triggers reactive oxygen species-dependent hypoxia-inducible factor activation and tumorigenesis. Mol Cell Biol 28 (2008), 718–731.
88. Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
89. Harada, H., Inoue, M., Itasaka, S., Hirota, K., Morinibu, A., Shinomiya, K. Hiraoka, M., Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels. Nat Commun, 3, 2012, 783.
90. Harada, H., Itasaka, S., Zhu, Y., Zeng, L., Xie, X., Morinibu, A. Hiraoka, M., Treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of radiation therapy. Br J Cancer 100 (2009), 747–757.
91. He, C., Sun, X.P., Qiao, H., Jiang, X., Wang, D., Jin, X. Sun, X., Downregulating hypoxia-inducible factor-2alpha improves the efficacy of doxorubicin in the treatment of hepatocellular carcinoma. Cancer Sci 103 (2012), 528–534.
92. Helczynska, K., Larsson, A.M., Holmquist Mengelbier, L., Bridges, E., Fredlund, E., Borgquist, S. Jirstrom, K., Hypoxia-inducible factor-2alpha correlates to distant recurrence and poor outcome in invasive breast cancer. Cancer Res 68 (2008), 9212–9220.
93. Hicks, K.O., Siim, B.G., Jaiswal, J.K., Pruijn, F.B., Fraser, A.M., Patel, R. Wilson, W.R., Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors. Clin Cancer Res 16 (2010), 4946–4957.
94. Hiraga, T., Kizaka-Kondoh, S., Hirota, K., Hiraoka, M., Yoneda, T., Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res 67 (2007), 4157–4163.
95. Hockel, M., Vaupel, P., Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93 (2001), 266–276.
96. Hockel, M., Knoop, C., Schlenger, K., Vorndran, B., Baussmann, E., Mitze, M. Vaupel, P., Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 26 (1993), 45–50.
97. Hockel, M., Schlenger, K., Aral, B., Mitze, M., Schaffer, U., Vaupel, P., Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56 (1996), 4509–4515.
98. Holmquist-Mengelbier, L., Fredlund, E., Lofstedt, T., Noguera, R., Navarro, S., Nilsson, H. Pahlman, S., Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell 10 (2006), 413–423.
99. Hu, Y.Y., Fu, L.A., Li, S.Z., Chen, Y., Li, J.C., Han, J. Han, H., Hif-1alpha and Hif-2alpha differentially regulate Notch signaling through competitive interaction with the intracellular domain of Notch receptors in glioma stem cells. Cancer Lett 349 (2014), 67–76.
100. Hu, C.J., Wang, L.Y., Chodosh, L.A., Keith, B., Simon, M.C., Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol 23 (2003), 9361–9374.
101. Hudson, C.C., Liu, M., Chiang, G.G., Otterness, D.M., Loomis, D.C., Kaper, F. Abraham, R.T., Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 22 (2002), 7004–7014.
102. Hunter, F.W., Young, R.J., Shalev, Z., Vellanki, R.N., Wang, J., Gu, Y. Wouters, B.G., Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs. Cancer Res 75 (2015), 4211–4223.
103. Hutt, D.M., Roth, D.M., Vignaud, H., Cullin, C., Bouchecareilh, M., The histone deacetylase inhibitor, Vorinostat, represses hypoxia inducible factor 1 alpha expression through translational inhibition. PLoS One, 9, 2014, e106224.
104. Imai, T., Horiuchi, A., Wang, C., Oka, K., Ohira, S., Nikaido, T., Konishi, I., Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells. Am J Pathol 163 (2003), 1437–1447.
105. Imtiyaz, H.Z., Williams, E.P., Hickey, M.M., Patel, S.A., Durham, A.C., Yuan, L.J. Simon, M.C., Hypoxia-inducible factor 2alpha regulates macrophage function in mouse models of acute and tumor inflammation. J Clin Invest 120 (2010), 2699–2714.
106. Isaacs, J.S., Jung, Y.J., Mimnaugh, E.G., Martinez, A., Cuttitta, F., Neckers, L.M., Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem 277 (2002), 29936–29944.
107. Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M. Kaelin, W.G. Jr., HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292 (2001), 464–468.
108. Iyer, N.V., Kotch, L.E., Agani, F., Leung, S.W., Laughner, E., Wenger, R.H. Semenza, G.L., Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev 12 (1998), 149–162.
109. Jaakkola, P., Mole, D.R., Tian, Y.M., Wilson, M.I., Gielbert, J., Gaskell, S.J. Ratcliffe, P.J., Targeting of HIF-alpha to the von Hippel–Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292 (2001), 468–472.
110. Jacks, T., Shih, T.S., Schmitt, E.M., Bronson, R.T., Bernards, A., Weinberg, R.A., Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet 7 (1994), 353–361.
111. Jeong, W., Rapisarda, A., Park, S.R., Kinders, R.J., Chen, A., Melillo, G. Kummar, S., Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1alpha), in patients with refractory solid tumors. Cancer Chemother Pharmacol 73 (2014), 343–348.
112. Jiang, B.H., Jiang, G., Zheng, J.Z., Lu, Z., Hunter, T., Vogt, P.K., Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ 12 (2001), 363–369.
113. Jogi, A., Ora, I., Nilsson, H., Lindeheim, A., Makino, Y., Poellinger, L. Pahlman, S., Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype. Proc Natl Acad Sci U S A 99 (2002), 7021–7026.
114. Johnson, R.W., Schipani, E., Giaccia, A.J., HIF targets in bone remodeling and metastatic disease. Pharmacol Ther 150 (2015), 169–177.
115. Jones, D.T., Pugh, C.W., Wigfield, S., Stevens, M.F., Harris, A.L., Novel thioredoxin inhibitors paradoxically increase hypoxia-inducible factor-alpha expression but decrease functional transcriptional activity, DNA binding, and degradation. Clin Cancer Res 12 (2006), 5384–5394.
116. Kaluz, S., Kaluzova, M., Stanbridge, E.J., Proteasomal inhibition attenuates transcriptional activity of hypoxia-inducible factor 1 (HIF-1) via specific effect on the HIF-1alpha C-terminal activation domain. Mol Cell Biol 26 (2006), 5895–5907.
117. Keith, B., Simon, M.C., Hypoxia-inducible factors, stem cells, and cancer. Cell 129 (2007), 465–472.
118. Keith, B., Johnson, R.S., Simon, M.C., HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 12 (2012), 9–22.
119. Kelly, B.D., Hackett, S.F., Hirota, K., Oshima, Y., Cai, Z., Berg-Dixon, S. Semenza, G.L., Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res 93 (2003), 1074–1081.
120. Khan, M.N., Bhattacharyya, T., Andrikopoulos, P., Esteban, M.A., Barod, R., Connor, T. Kiriakidis, S., Factor inhibiting HIF (FIH-1) promotes renal cancer cell survival by protecting cells from HIF-1alpha-mediated apoptosis. Br J Cancer 104 (2011), 1151–1159.
121. Khanna, C., Jaboin, J.J., Drakos, E., Tsokos, M., Thiele, C.J., Biologically relevant orthotopic neuroblastoma xenograft models: primary adrenal tumor growth and spontaneous distant metastasis. In Vivo 16 (2002), 77–85.
122. Kietzmann, T., Mennerich, D., Dimova, E.Y., Hypoxia-Inducible Factors (HIFs) and Phosphorylation: Impact on Stability, Localization, and Transactivity. Front Cell Dev Biol, 4, 2016, 11.
123. Kim, J.W., Tchernyshyov, I., Semenza, G.L., Dang, C.V., HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 3 (2006), 177–185.
124. King, K.S., Prodanov, T., Kantorovich, V., Fojo, T., Hewitt, J.K., Zacharin, M. Pacak, K., Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations. J Clin Oncol 29 (2011), 4137–4142.
125. Koh, M.Y., Powis, G., Passing the baton: the HIF switch. Trends Biochem Sci 37 (2012), 364–372.
126. Koh, M.Y., Lemos, R. Jr., Liu, X., Powis, G., The hypoxia-associated factor switches cells from HIF-1alpha- to HIF-2alpha-dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion. Cancer Res 71 (2011), 4015–4027.
127. Koh, M.Y., Spivak-Kroizman, T., Venturini, S., Welsh, S., Williams, R.R., Kirkpatrick, D.L., Powis, G., Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha. Mol Cancer Ther 7 (2008), 90–100.
128. Kondo, K., Kim, W.Y., Lechpammer, M., Kaelin, W.G. Jr., Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol, 1, 2003, E83.
129. Kong, D., Park, E.J., Stephen, A.G., Calvani, M., Cardellina, J.H., Monks, A. Melillo, G., Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res 65 (2005), 9047–9055.
130. Korpershoek, E., Loonen, A.J., Corvers, S., van Nederveen, F.H., Jonkers, J., Ma, X. de Krijger, R.R., Conditional Pten knock-out mice: a model for metastatic phaeochromocytoma. J Pathol 217 (2009), 597–604.
131. Korpershoek, E., Pacak, K., Martiniova, L., Murine models and cell lines for the investigation of pheochromocytoma: applications for future therapies?. Endocr Pathol 23 (2012), 43–54.
132. Koshiji, M., To, K.K., Hammer, S., Kumamoto, K., Harris, A.L., Modrich, P., Huang, L.E., HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression. Mol Cell 17 (2005), 793–803.
133. Koshiji, M., Kageyama, Y., Pete, E.A., Horikawa, I., Barrett, J.C., Huang, L.E., HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J 23 (2004), 1949–1956.
134. Koukourakis, M.I., Giatromanolaki, A., Sivridis, E., Simopoulos, C., Turley, H., Talks, K. Harris, A.L., Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys 53 (2002), 1192–1202.
135. Krieg, M., Haas, R., Brauch, H., Acker, T., Flamme, I., Plate, K.H., Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel–Lindau tumor suppressor gene loss of function. Oncogene 19 (2000), 5435–5443.
136. Krishnamachary, B., Berg-Dixon, S., Kelly, B., Agani, F., Feldser, D., Ferreira, G. Semenza, G.L., Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res 63 (2003), 1138–1143.
137. Krishnamachary, B., Zagzag, D., Nagasawa, H., Rainey, K., Okuyama, H., Baek, J.H., Semenza, G.L., Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel–Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res 66 (2006), 2725–2731.
138. Kronblad, A., Jirstrom, K., Ryden, L., Nordenskjold, B., Landberg, G., Hypoxia inducible factor-1alpha is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response. Int J Cancer 118 (2006), 2609–2616.
139. Kumar, G.K., Overholt, J.L., Bright, G.R., Hui, K.Y., Lu, H., Gratzl, M., Prabhakar, N.R., Release of dopamine and norepinephrine by hypoxia from PC-12 cells. Am J Phys 274 (1998), C1592–C1600.
140. Kummar, S., Chen, A., Ji, J., Zhang, Y., Reid, J.M., Ames, M. Doroshow, J.H., Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res 71 (2011), 5626–5634.
141. Kung, A.L., Zabludoff, S.D., France, D.S., Freedman, S.J., Tanner, E.A., Vieira, A. Livingston, D.M., Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 6 (2004), 33–43.
142. Landis, S.C., Patterson, P.H., Neural Crest Cell Lineages. Trends Neurosci 4 (1981), 172–175.
143. Lando, D., Peet, D.J., Gorman, J.J., Whelan, D.A., Whitelaw, M.L., Bruick, R.K., FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 16 (2002), 1466–1471.
144. LaVallee, T.M., Burke, P.A., Swartz, G.M., Hamel, E., Agoston, G.E., Shah, J. Treston, A.M., Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198. Mol Cancer Ther 7 (2008), 1472–1482.
145. Lee, S.H., Jee, J.G., Bae, J.S., Liu, K.H., Lee, Y.M., A group of novel HIF-1alpha inhibitors, glyceollins, blocks HIF-1alpha synthesis and decreases its stability via inhibition of the PI3K/AKT/mTOR pathway and Hsp90 binding. J Cell Physiol 230 (2015), 853–862.
146. Lee, J., Kotliarova, S., Kotliarov, Y., Li, A., Su, Q., Donin, N.M. Fine, H.A., Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9 (2006), 391–403.
147. Lee, K., Zhang, H., Qian, D.Z., Rey, S., Liu, J.O., Semenza, G.L., Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc Natl Acad Sci U S A 106 (2009), 17910–17915.
148. Li, Z., Bao, S., Wu, Q., Wang, H., Eyler, C., Sathornsumetee, S. Rich, J.N., Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 15 (2009), 501–513.
149. Li, S.H., Shin, D.H., Chun, Y.S., Lee, M.K., Kim, M.S., Park, J.W., A novel mode of action of YC-1 in HIF inhibition: stimulation of FIH-dependent p300 dissociation from HIF-1{alpha}. Mol Cancer Ther 7 (2008), 3729–3738.
150. Liao, D., Corle, C., Seagroves, T.N., Johnson, R.S., Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res 67 (2007), 563–572.
151. Lofstedt, T., Fredlund, E., Holmquist-Mengelbier, L., Pietras, A., Ovenberger, M., Poellinger, L., Pahlman, S., Hypoxia inducible factor-2alpha in cancer. Cell Cycle 6 (2007), 919–926.
152. Lopez-Jimenez, E., Gomez-Lopez, G., Leandro-Garcia, L.J., Munoz, I., Schiavi, F., Montero-Conde, C. Cascon, A., Research resource: transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas. Mol Endocrinol 24 (2010), 2382–2391.
153. Lopez-Lazaro, M., Digoxin, HIF-1, and cancer. Proc Natl Acad Sci U S A, 106, 2009, E26 (author reply E27).
154. Lorenzo, F.R., Yang, C., Ng Tang Fui, M., Vankayalapati, H., Zhuang, Z., Huynh, T. Prchal, J.T., A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma. J Mol Med (Berl) 91 (2013), 507–512.
155. Lu, Y., Chu, A., Turker, M.S., Glazer, P.M., Hypoxia-induced epigenetic regulation and silencing of the BRCA1 promoter. Mol Cell Biol 31 (2011), 3339–3350.
156. Lu, X., Yan, C.H., Yuan, M., Wei, Y., Hu, G., Kang, Y., In vivo dynamics and distinct functions of hypoxia in primary tumor growth and organotropic metastasis of breast cancer. Cancer Res 70 (2010), 3905–3914.
157. Ma, L., Li, G., Zhu, H., Dong, X., Zhao, D., Jiang, X. Sun, X., 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2. Cancer Lett 355 (2014), 96–105.
158. Mabjeesh, N.J., Escuin, D., LaVallee, T.M., Pribluda, V.S., Swartz, G.M., Johnson, M.S. Giannakakou, P., 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3 (2003), 363–375.
159. Mackay, H., Hedley, D., Major, P., Townsley, C., Mackenzie, M., Vincent, M. Oza, A., A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. Clin Cancer Res 11 (2005), 5526–5533.
160. Maher, L.J. III, Smith, E.H., Rueter, E.M., Becker, N.A., Bida, J.P., Nelson-Holte, M., Piruat Palomo, J.I., García-Flores, P., López-Barneo, J. van Deursen, J., Mouse models of human familial paraganglioma. Martin, C.M.J.F., (eds.) Pheochromocytoma — a New View of the Old Problem, 2011, InTech.
161. Mahon, P.C., Hirota, K., Semenza, G.L., FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 15 (2001), 2675–2686.
162. Majumder, P.K., Febbo, P.G., Bikoff, R., Berger, R., Xue, Q., McMahon, L.M. Sellers, W.R., mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10 (2004), 594–601.
163. Marchiq, I., Pouyssegur, J., Hypoxia, cancer metabolism and the therapeutic benefit of targeting lactate/H(+) symporters. J Mol Med (Berl) 94 (2016), 155–171.
164. Martin, C.M., Ferdous, A., Gallardo, T., Humphries, C., Sadek, H., Caprioli, A. Garry, D.J., Hypoxia-inducible factor-2alpha transactivates Abcg2 and promotes cytoprotection in cardiac side population cells. Circ Res 102 (2008), 1075–1081.
165. Masoud, G.N., Wang, J., Chen, J., Miller, D., Li, W., Design, synthesis and biological evaluation of novel HIF1alpha inhibitors. Anticancer Res 35 (2015), 3849–3859.
166. Masson, N., Ratcliffe, P.J., Hypoxia signaling pathways in cancer metabolism: the importance of co-selecting interconnected physiological pathways. Cancer Metab, 2, 2014, 3.
167. Mayer, A., Hockel, M., Vaupel, P., Endogenous hypoxia markers: case not proven!. Adv Exp Med Biol 614 (2008), 127–136.
168. Mayer, A., Hockel, M., Wree, A., Leo, C., Horn, L.C., Vaupel, P., Lack of hypoxic response in uterine leiomyomas despite severe tissue hypoxia. Cancer Res 68 (2008), 4719–4726.
169. Meijer, T.W., Kaanders, J.H., Span, P.N., Bussink, J., Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. Clin Cancer Res 18 (2012), 5585–5594.
170. Melillo, G., Targeting hypoxia cell signaling for cancer therapy. Cancer Metastasis Rev 26 (2007), 341–352.
171. Moeller, B.J., Cao, Y., Li, C.Y., Dewhirst, M.W., Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5 (2004), 429–441.
172. Moeller, B.J., Dreher, M.R., Rabbani, Z.N., Schroeder, T., Cao, Y., Li, C.Y., Dewhirst, M.W., Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 8 (2005), 99–110.
173. Mohlin, S., Hamidian, A., Pahlman, S., HIF2A and IGF2 expression correlates in human neuroblastoma cells and normal immature sympathetic neuroblasts. Neoplasia 15 (2013), 328–334.
174. Mohlin, S., Hamidian, A., von Stedingk, K., Bridges, E., Wigerup, C., Bexell, D., Pahlman, S., PI3K-mTORC2 but not PI3K-mTORC1 regulates transcription of HIF2A/EPAS1 and vascularization in neuroblastoma. Cancer Res 75 (2015), 4617–4628.
175. Mole, D.R., Blancher, C., Copley, R.R., Pollard, P.J., Gleadle, J.M., Ragoussis, J., Ratcliffe, P.J., Genome-wide association of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha DNA binding with expression profiling of hypoxia-inducible transcripts. J Biol Chem 284 (2009), 16767–16775.
176. Molenaar, J.J., Domingo-Fernandez, R., Ebus, M.E., Lindner, S., Koster, J., Drabek, K. Schulte, J.H., LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nat Genet 44 (2012), 1199–1206.
177. Moreno-Manzano, V., Rodriguez-Jimenez, F.J., Acena-Bonilla, J.L., Fustero-Lardies, S., Erceg, S., Dopazo, J. Sanchez-Puelles, J.M., FM19G11, a new hypoxia-inducible factor (HIF) modulator, affects stem cell differentiation status. J Biol Chem 285 (2010), 1333–1342.
178. Muller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M.E. Zlotnik, A., Involvement of chemokine receptors in breast cancer metastasis. Nature 410 (2001), 50–56.
179. Munoz-Najar, U.M., Neurath, K.M., Vumbaca, F., Claffey, K.P., Hypoxia stimulates breast carcinoma cell invasion through MT1-MMP and MMP-2 activation. Oncogene 25 (2006), 2379–2392.
180. Nardinocchi, L., Puca, R., Sacchi, A., D'Orazi, G., Inhibition of HIF-1alpha activity by homeodomain-interacting protein kinase-2 correlates with sensitization of chemoresistant cells to undergo apoptosis. Mol Cancer, 8, 2009, 1.
181. Nilsson, H., Jogi, A., Beckman, S., Harris, A.L., Poellinger, L., Pahlman, S., HIF-2alpha expression in human fetal paraganglia and neuroblastoma: relation to sympathetic differentiation, glucose deficiency, and hypoxia. Exp Cell Res 303 (2005), 447–456.
182. Noguera, R., Fredlund, E., Piqueras, M., Pietras, A., Beckman, S., Navarro, S., Pahlman, S., HIF-1alpha and HIF-2alpha are differentially regulated in vivo in neuroblastoma: high HIF-1alpha correlates negatively to advanced clinical stage and tumor vascularization. Clin Cancer Res 15 (2009), 7130–7136.
183. Noman, M.Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P. Chouaib, S., PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med 211 (2014), 781–790.
184. Nordsmark, M., Alsner, J., Keller, J., Nielsen, O.S., Jensen, O.M., Horsman, M.R., Overgaard, J., Hypoxia in human soft tissue sarcomas: adverse impact on survival and no association with p53 mutations. Br J Cancer 84 (2001), 1070–1075.
185. Nordsmark, M., Bentzen, S.M., Rudat, V., Brizel, D., Lartigau, E., Stadler, P. Overgaard, J., Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 77 (2005), 18–24.
186. Nordsmark, M., Loncaster, J., Aquino-Parsons, C., Chou, S.C., Gebski, V., West, C. Overgaard, J., The prognostic value of pimonidazole and tumour pO2 in human cervix carcinomas after radiation therapy: a prospective international multi-center study. Radiother Oncol 80 (2006), 123–131.
187. Norris, R.E., Shusterman, S., Gore, L., Muscal, J.A., Macy, M.E., Fox, E. Bagatell, R., Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors. Pediatr Blood Cancer 61 (2014), 1792–1797.
188. Olenyuk, B.Z., Zhang, G.J., Klco, J.M., Nickols, N.G., Kaelin, W.G. Jr., Dervan, P.B., Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. Proc Natl Acad Sci U S A 101 (2004), 16768–16773.
189. Onnis, B., Rapisarda, A., Melillo, G., Development of HIF-1 inhibitors for cancer therapy. J Cell Mol Med 13 (2009), 2780–2786.
190. Palazon, A., Aragones, J., Morales-Kastresana, A., de Landazuri, M.O., Melero, I., Molecular pathways: hypoxia response in immune cells fighting or promoting cancer. Clin Cancer Res 18 (2012), 1207–1213.
191. Pastorino, F., Loi, M., Sapra, P., Becherini, P., Cilli, M., Emionite, L. Ponzoni, M., Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor. Clin Cancer Res 16 (2010), 4809–4821.
192. Pellegata, N.S., Quintanilla-Martinez, L., Siggelkow, H., Samson, E., Bink, K., Hofler, H. Atkinson, M.J., Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci U S A 103 (2006), 15558–15563.
193. Peng, J., Zhang, L., Drysdale, L., Fong, G.H., The transcription factor EPAS-1/hypoxia-inducible factor 2alpha plays an important role in vascular remodeling. Proc Natl Acad Sci U S A 97 (2000), 8386–8391.
194. Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., Comoglio, P.M., Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3 (2003), 347–361.
195. Phillips, R.M., Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs. Cancer Chemother Pharmacol 77 (2016), 441–457.
196. Phillips, R.M., Hendriks, H.R., Peters, G.J., Pharmacology, E., Molecular Mechanism, G., EO9 (Apaziquone): from the clinic to the laboratory and back again. Br J Pharmacol 168 (2013), 11–18.
197. Pietras, A., Gisselsson, D., Ora, I., Noguera, R., Beckman, S., Navarro, S., Pahlman, S., High levels of HIF-2alpha highlight an immature neural crest-like neuroblastoma cell cohort located in a perivascular niche. J Pathol 214 (2008), 482–488.
198. Pietras, A., Hansford, L.M., Johnsson, A.S., Bridges, E., Sjolund, J., Gisselsson, D. Pahlman, S., HIF-2alpha maintains an undifferentiated state in neural crest-like human neuroblastoma tumor-initiating cells. Proc Natl Acad Sci U S A 106 (2009), 16805–16810.
199. Pietras, A., Johnsson, A.S., Pahlman, S., The HIF-2alpha-driven pseudo-hypoxic phenotype in tumor aggressiveness, differentiation, and vascularization. Curr Top Microbiol Immunol 345 (2010), 1–20.
200. Piruat, J.I., Pintado, C.O., Ortega-Saenz, P., Roche, M., Lopez-Barneo, J., The mitochondrial SDHD gene is required for early embryogenesis, and its partial deficiency results in persistent carotid body glomus cell activation with full responsiveness to hypoxia. Mol Cell Biol 24 (2004), 10933–10940.
201. Pouyssegur, J., Dayan, F., Mazure, N.M., Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441 (2006), 437–443.
202. Powers, J.F., Evinger, M.J., Tsokas, P., Bedri, S., Alroy, J., Shahsavari, M., Tischler, A.S., Pheochromocytoma cell lines from heterozygous neurofibromatosis knockout mice. Cell Tissue Res 302 (2000), 309–320.
203. Qin, N., de Cubas, A.A., Garcia-Martin, R., Richter, S., Peitzsch, M., Menschikowski, M. Eisenhofer, G., Opposing effects of HIF1alpha and HIF2alpha on chromaffin cell phenotypic features and tumor cell proliferation: insights from MYC-associated factor X. Int J Cancer 135 (2014), 2054–2064.
204. Ramanathan, R.K., Abbruzzese, J., Dragovich, T., Kirkpatrick, L., Guillen, J.M., Baker, A.F. Von Hoff, D.D., A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination. Cancer Chemother Pharmacol 67 (2011), 503–509.
205. Rankin, E.B., Biju, M.P., Liu, Q., Unger, T.L., Rha, J., Johnson, R.S. Haase, V.H., Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J Clin Invest 117 (2007), 1068–1077.
206. Rapisarda, A., Uranchimeg, B., Scudiero, D.A., Selby, M., Sausville, E.A., Shoemaker, R.H., Melillo, G., Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 62 (2002), 4316–4324.
207. Rapisarda, A., Zalek, J., Hollingshead, M., Braunschweig, T., Uranchimeg, B., Bonomi, C.A. Melillo, G., Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res 64 (2004), 6845–6848.
208. Raskatov, J.A., Szablowski, J.O., Dervan, P.B., Tumor xenograft uptake of a pyrrole-imidazole (Py-Im) polyamide varies as a function of cell line grafted. J Med Chem 57 (2014), 8471–8476.
209. Raval, R.R., Lau, K.W., Tran, M.G., Sowter, H.M., Mandriota, S.J., Li, J.L. Ratcliffe, P.J., Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel–Lindau-associated renal cell carcinoma. Mol Cell Biol 25 (2005), 5675–5686.
210. Ravi, R., Mookerjee, B., Bhujwalla, Z.M., Sutter, C.H., Artemov, D., Zeng, Q. Bedi, A., Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 14 (2000), 34–44.
211. Reece, K.M., Richardson, E.D., Cook, K.M., Campbell, T.J., Pisle, S.T., Holly, A.J. Figg, W.D., Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1alpha/p300 complex in a preclinical model of prostate cancer. Mol Cancer, 13, 2014, 91.
212. Reynolds, T.Y., Rockwell, S., Glazer, P.M., Genetic instability induced by the tumor microenvironment. Cancer Res 56 (1996), 5754–5757.
213. Richter, S., Qin, N., Pacak, K., Eisenhofer, G., Role of hypoxia and HIF2alpha in development of the sympathoadrenal cell lineage and chromaffin cell tumors with distinct catecholamine phenotypic features. Adv Pharmacol 68 (2013), 285–317.
214. Rischin, D., Peters, L.J., O'Sullivan, B., Giralt, J., Fisher, R., Yuen, K. Kenny, L., Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol 28 (2010), 2989–2995.
215. Roberts, A.M., Watson, I.R., Evans, A.J., Foster, D.A., Irwin, M.S., Ohh, M., Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells. Cancer Res 69 (2009), 9056–9064.
216. Rohwer, N., Cramer, T., Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat 14 (2011), 191–201.
217. Roizin-Towle, L., Hall, E.J., Studies with bleomycin and misonidazole on aerated and hypoxic cells. Br J Cancer 37 (1978), 254–260.
218. Rundqvist, H., Johnson, R.S., Hypoxia and metastasis in breast cancer. Curr Top Microbiol Immunol 345 (2010), 121–139.
219. Ryan, H.E., Lo, J., Johnson, R.S., HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J 17 (1998), 3005–3015.
220. Sanchez, M., Galy, B., Muckenthaler, M.U., Hentze, M.W., Iron-regulatory proteins limit hypoxia-inducible factor-2alpha expression in iron deficiency. Nat Struct Mol Biol 14 (2007), 420–426.
221. Scheuermann, T.H., Li, Q., Ma, H.W., Key, J., Zhang, L., Chen, R. Bruick, R.K., Allosteric inhibition of hypoxia inducible factor-2 with small molecules. Nat Chem Biol 9 (2013), 271–276.
222. Scheuermann, T.H., Tomchick, D.R., Machius, M., Guo, Y., Bruick, R.K., Gardner, K.H., Artificial ligand binding within the HIF2alpha PAS-B domain of the HIF2 transcription factor. Proc Natl Acad Sci U S A 106 (2009), 450–455.
223. Schindl, M., Schoppmann, S.F., Samonigg, H., Hausmaninger, H., Kwasny, W., Gnant, M. Colorectal Cancer Study, G., Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 8 (2002), 1831–1837.
224. Schnell, P.O., Ignacak, M.L., Bauer, A.L., Striet, J.B., Paulding, W.R., Czyzyk-Krzeska, M.F., Regulation of tyrosine hydroxylase promoter activity by the von Hippel–Lindau tumor suppressor protein and hypoxia-inducible transcription factors. J Neurochem 85 (2003), 483–491.
225. Schodel, J., Oikonomopoulos, S., Ragoussis, J., Pugh, C.W., Ratcliffe, P.J., Mole, D.R., High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq. Blood 117 (2011), e207–e217.
226. Schofield, C.J., Ratcliffe, P.J., Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 5 (2004), 343–354.
227. Schoppmann, S.F., Fenzl, A., Schindl, M., Bachleitner-Hofmann, T., Nagy, K., Gnant, M. Birner, P., Hypoxia inducible factor-1alpha correlates with VEGF-C expression and lymphangiogenesis in breast cancer. Breast Cancer Res Treat 99 (2006), 135–141.
228. Schulz, N., Propst, F., Rosenberg, M.P., Linnoila, R.I., Paules, R.S., Kovatch, R. Vande Woude, G., Pheochromocytomas and C-cell thyroid neoplasms in transgenic c-mos mice: a model for the human multiple endocrine neoplasia type 2 syndrome. Cancer Res 52 (1992), 450–455.
229. Scortegagna, M., Ding, K., Oktay, Y., Gaur, A., Thurmond, F., Yan, L.J. Garcia, J.A., Multiple organ pathology, metabolic abnormalities and impaired homeostasis of reactive oxygen species in Epas1−/− mice. Nat Genet 35 (2003), 331–340.
230. Semenza, G.L., Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3 (2003), 721–732.
231. Semenza, G.L., Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 33 (2012), 207–214.
232. Semenza, G.L., HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest 123 (2013), 3664–3671.
233. Shin, D.H., Chun, Y.S., Lee, D.S., Huang, L.E., Park, J.W., Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. Blood 111 (2008), 3131–3136.
234. Shin, D.H., Kim, J.H., Jung, Y.J., Kim, K.E., Jeong, J.M., Chun, Y.S., Park, J.W., Preclinical evaluation of YC-1, a HIF inhibitor, for the prevention of tumor spreading. Cancer Lett 255 (2007), 107–116.
235. Shultz, L.D., Goodwin, N., Ishikawa, F., Hosur, V., Lyons, B.L., Greiner, D.L., Human cancer growth and therapy in immunodeficient mouse models. Cold Spring Harb Protoc 2014 (2014), 694–708.
236. Shweiki, D., Itin, A., Soffer, D., Keshet, E., Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359 (1992), 843–845.
237. Simiantonaki, N., Taxeidis, M., Jayasinghe, C., Kurzik-Dumke, U., Kirkpatrick, C.J., Hypoxia-inducible factor 1 alpha expression increases during colorectal carcinogenesis and tumor progression. BMC Cancer, 8, 2008, 320.
238. Singleton, D.C., Rouhi, P., Zois, C.E., Haider, S., Li, J.L., Kessler, B.M. Harris, A.L., Hypoxic regulation of RIOK3 is a major mechanism for cancer cell invasion and metastasis. Oncogene 34 (2015), 4713–4722.
239. Sivridis, E., Giatromanolaki, A., Gatter, K.C., Harris, A.L., Koukourakis, M.I., Tumor, & Angiogenesis Research, G., Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer 95 (2002), 1055–1063.
240. Smith-Hicks, C.L., Sizer, K.C., Powers, J.F., Tischler, A.S., Costantini, F., C-cell hyperplasia, pheochromocytoma and sympathoadrenal malformation in a mouse model of multiple endocrine neoplasia type 2B. EMBO J 19 (2000), 612–622.
241. Staller, P., Sulitkova, J., Lisztwan, J., Moch, H., Oakeley, E.J., Krek, W., Chemokine receptor CXCR4 downregulated by von Hippel–Lindau tumour suppressor pVHL. Nature 425 (2003), 307–311.
242. Sullivan, R., Graham, C.H., Hypoxia prevents etoposide-induced DNA damage in cancer cells through a mechanism involving hypoxia-inducible factor 1. Mol Cancer Ther 8 (2009), 1702–1713.
243. Taieb, D., Yang, C., Delenne, B., Zhuang, Z., Barlier, A., Sebag, F., Pacak, K., First report of bilateral pheochromocytoma in the clinical spectrum of HIF2A-related polycythemia–paraganglioma syndrome. J Clin Endocrinol Metab 98 (2013), E908–E913.
244. Tannock, I.F., The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumour. Br J Cancer 22 (1968), 258–273.
245. Teitz, T., Inoue, M., Valentine, M.B., Zhu, K., Rehg, J.E., Zhao, W. Lahti, J.M., Th-MYCN mice with caspase-8 deficiency develop advanced neuroblastoma with bone marrow metastasis. Cancer Res 73 (2013), 4086–4097.
246. Terzuoli, E., Puppo, M., Rapisarda, A., Uranchimeg, B., Cao, L., Burger, A.M. Melillo, G., Aminoflavone, a ligand of the aryl hydrocarbon receptor, inhibits HIF-1alpha expression in an AhR-independent fashion. Cancer Res 70 (2010), 6837–6848.
247. Thomas, G.V., Tran, C., Mellinghoff, I.K., Welsbie, D.S., Chan, E., Fueger, B. Sawyers, C.L., Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12 (2006), 122–127.
248. Tian, H., Hammer, R.E., Matsumoto, A.M., Russell, D.W., McKnight, S.L., The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev 12 (1998), 3320–3324.
249. Tian, H., McKnight, S.L., Russell, D.W., Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 11 (1997), 72–82.
250. To, K.K., Sedelnikova, O.A., Samons, M., Bonner, W.M., Huang, L.E., The phosphorylation status of PAS-B distinguishes HIF-1alpha from HIF-2alpha in NBS1 repression. EMBO J 25 (2006), 4784–4794.
251. Toledo, R.A., Qin, Y., Srikantan, S., Morales, N.P., Li, Q., Deng, Y. Dahia, P.L., In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas. Endocr Relat Cancer 20 (2013), 349–359.
252. Uniacke, J., Holterman, C.E., Lachance, G., Franovic, A., Jacob, M.D., Fabian, M.R. Lee, S., An oxygen-regulated switch in the protein synthesis machinery. Nature 486 (2012), 126–129.
253. Unruh, A., Ressel, A., Mohamed, H.G., Johnson, R.S., Nadrowitz, R., Richter, E. Wenger, R.H., The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 22 (2003), 3213–3220.
254. Vander Heiden, M.G., Cantley, L.C., Thompson, C.B., Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324 (2009), 1029–1033.
255. Vaupel, P., Mayer, A., Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 26 (2007), 225–239.
256. Vaupel, P., Mayer, A., Hockel, M., Tumor hypoxia and malignant progression. Methods Enzymol 381 (2004), 335–354.
257. Vergis, R., Corbishley, C.M., Norman, A.R., Bartlett, J., Jhavar, S., Borre, M. Parker, C., Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol 9 (2008), 342–351.
258. Volm, M., Koomagi, R., Hypoxia-inducible factor (HIF-1) and its relationship to apoptosis and proliferation in lung cancer. Anticancer Res 20 (2000), 1527–1533.
259. Wang, G.L., Jiang, B.H., Rue, E.A., Semenza, G.L., Hypoxia-inducible factor 1 is a basic-helix–loop–helix–PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 92 (1995), 5510–5514.
260. Wang, Y., Liu, Y., Tang, F., Bernot, K.M., Schore, R., Marcucci, G. Liu, Y., Echinomycin protects mice against relapsed acute myeloid leukemia without adverse effect on hematopoietic stem cells. Blood 124 (2014), 1127–1135.
261. Weiss, W.A., Aldape, K., Mohapatra, G., Feuerstein, B.G., Bishop, J.M., Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 16 (1997), 2985–2995.
262. Welsh, S.J., Bellamy, W.T., Briehl, M.M., Powis, G., The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res 62 (2002), 5089–5095.
263. Welsh, S.J., Williams, R.R., Birmingham, A., Newman, D.J., Kirkpatrick, D.L., Powis, G., The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Mol Cancer Ther 2 (2003), 235–243.
264. Welsh, S., Williams, R., Kirkpatrick, L., Paine-Murrieta, G., Powis, G., Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol Cancer Ther 3 (2004), 233–244.
265. White, E., Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer 12 (2012), 401–410.
266. Wilson, W.R., Hay, M.P., Targeting hypoxia in cancer therapy. Nat Rev Cancer 11 (2011), 393–410.
267. Xia, X., Kung, A.L., Preferential binding of HIF-1 to transcriptionally active loci determines cell-type specific response to hypoxia. Genome Biol, 10, 2009, R113.
268. Xia, X., Lemieux, M.E., Li, W., Carroll, J.S., Brown, M., Liu, X.S., Kung, A.L., Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis. Proc Natl Acad Sci U S A 106 (2009), 4260–4265.
269. Yang, C., Sun, M.G., Matro, J., Huynh, T.T., Rahimpour, S., Prchal, J.T. Zhuang, Z., Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas. Blood 121 (2013), 2563–2566.
270. Yang, M.H., Wu, M.Z., Chiou, S.H., Chen, P.M., Chang, S.Y., Liu, C.J. Wu, K.J., Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol 10 (2008), 295–305.
271. Yeo, E.J., Chun, Y.S., Cho, Y.S., Kim, J., Lee, J.C., Kim, M.S., Park, J.W., YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 95 (2003), 516–525.
272. Yeo, E.J., Ryu, J.H., Cho, Y.S., Chun, Y.S., Huang, L.E., Kim, M.S., Park, J.W., Amphotericin B blunts erythropoietin response to hypoxia by reinforcing FIH-mediated repression of HIF-1. Blood 107 (2006), 916–923.
273. You, M.J., Castrillon, D.H., Bastian, B.C., O'Hagan, R.C., Bosenberg, M.W., Parsons, R. DePinho, R.A., Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice. Proc Natl Acad Sci U S A 99 (2002), 1455–1460.
274. Young, S.D., Marshall, R.S., Hill, R.P., Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells. Proc Natl Acad Sci U S A 85 (1988), 9533–9537.
275. Yuan, J., Narayanan, L., Rockwell, S., Glazer, P.M., Diminished DNA repair and elevated mutagenesis in mammalian cells exposed to hypoxia and low pH. Cancer Res 60 (2000), 4372–4376.
276. Yuneva, M., Zamboni, N., Oefner, P., Sachidanandam, R., Lazebnik, Y., Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J Cell Biol 178 (2007), 93–105.
277. Zhang, H., Bosch-Marce, M., Shimoda, L.A., Tan, Y.S., Baek, J.H., Wesley, J.B. Semenza, G.L., Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J Biol Chem 283 (2008), 10892–10903.
278. Zhang, H., Gao, P., Fukuda, R., Kumar, G., Krishnamachary, B., Zeller, K.I. Semenza, G.L., HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 11 (2007), 407–420.
279. Zhang, X., Kon, T., Wang, H., Li, F., Huang, Q., Rabbani, Z.N. Li, C.Y., Enhancement of hypoxia-induced tumor cell death in vitro and radiation therapy in vivo by use of small interfering RNA targeted to hypoxia-inducible factor-1alpha. Cancer Res 64 (2004), 8139–8142.
280. Zhang, H., Qian, D.Z., Tan, Y.S., Lee, K., Gao, P., Ren, Y.R. Semenza, G.L., Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci U S A 105 (2008), 19579–19586.
281. Zhang, H., Wong, C.C., Wei, H., Gilkes, D.M., Korangath, P., Chaturvedi, P. Semenza, G.L., HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs. Oncogene 31 (2012), 1757–1770.
282. Zhao, D., Zhai, B., He, C., Tan, G., Jiang, X., Pan, S. Sun, X., Upregulation of HIF-2alpha induced by sorafenib contributes to the resistance by activating the TGF-alpha/EGFR pathway in hepatocellular carcinoma cells. Cell Signal 26 (2014), 1030–1039.
283. Zhong, H., Agani, F., Baccala, A.A., Laughner, E., Rioseco-Camacho, N., Isaacs, W.B. Semenza, G.L., Increased expression of hypoxia inducible factor-1alpha in rat and human prostate cancer. Cancer Res 58 (1998), 5280–5284.
284. Zhong, H., Chiles, K., Feldser, D., Laughner, E., Hanrahan, C., Georgescu, M.M. Semenza, G.L., Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60 (2000), 1541–1545.
285. Zhong, H., De Marzo, A.M., Laughner, E., Lim, M., Hilton, D.A., Zagzag, D. Simons, J.W., Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59 (1999), 5830–5835.
286. Zhou, Q., Gustafson, D., Nallapareddy, S., Diab, S., Leong, S., Lewis, K. Camidge, D.R., A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer. Investig New Drugs 29 (2011), 340–346.
287. Zhou, Z.L., Luo, Z.G., Yu, B., Jiang, Y., Chen, Y., Feng, J.M. Miao, Z.H., Increased accumulation of hypoxia-inducible factor-1alpha with reduced transcriptional activity mediates the antitumor effect of triptolide. Mol Cancer, 9, 2010, 268.
288. Zhuang, Z., Yang, C., Lorenzo, F., Merino, M., Fojo, T., Kebebew, E. Pacak, K., Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N Engl J Med 367 (2012), 922–930.
289. Zimmer, M., Ebert, B.L., Neil, C., Brenner, K., Papaioannou, I., Melas, A. Iliopoulos, O., Small-molecule inhibitors of HIF-2a translation link its 5′UTR iron-responsive element to oxygen sensing. Mol Cell 32 (2008), 838–848.